Physician profile
Rex A Newcomb
NPI 1891771390
$1,580.17
in general payments reported to CMS, 2019-2025
12 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $200 · 2021: $272 · 2022: $210 · 2023: $227 · 2024: $410 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $528.08 | 2022-2025 | Myday Contact Lens, Biofinity Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $315.81 | 2020-2021 | |
| Sight Sciences, INC. | $226.03 | 2024-2025 | Tearcare System, Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $96.14 | 2024 | |
| Allergan, INC. | $95.29 | 2022 | |
| Abbvie INC. | $92.16 | 2024 | |
| Alcon Vision LLC | $90.18 | 2020 | |
| Bausch & Lomb Americas INC. | $56.54 | 2024-2025 | Infuse |
| Maculogix, INC. | $31.81 | 2020 | |
| Novartis Pharmaceuticals Corporation | $22.98 | 2021 | |
| Dompe US, INC. | $14.24 | 2025 | Oxervate |
| Abb Con-Cise Optical Group LLC | $10.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rex Newcomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.